Therefore, using CRISPR-dCas9-Tet1 system for targeting demethylation of nicotinamide nucleotide transhydrogenase (NNT) CpG island in A549/DDP cells is established to suppress the autophagy and cisplatin resistance as a first-line chemotherapeutic agent for treting advanced non-small cell lung cancer (Xu et al. 2023). This evidence concerns the gene NNT and non-small cell lung carcinoma.